Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].

Seitz S, Buchholz S, Schally AV, Jayakumar AR, Weber F, Papadia A, Rick FG, Szalontay L, Treszl A, Köster F, Ortmann O, Hohla F.

Anticancer Drugs. 2013 Feb;24(2):150-7. doi: 10.1097/CAD.0b013e32835a7e29.

PMID:
23080077
2.

Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.

Seitz S, Schally AV, Treszl A, Papadia A, Rick F, Szalontay L, Szepeshazi K, Ortmann O, Halmos G, Hohla F, Buchholz S.

Anticancer Drugs. 2009 Aug;20(7):553-8. doi: 10.1097/CAD.0b013e32832d190b.

PMID:
19491659
3.

The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.

Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S.

Horm Metab Res. 2010 Oct;42(11):781-6. doi: 10.1055/s-0030-1261955. Epub 2010 Jul 27.

PMID:
20665426
4.

Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.

Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.

BMC Cancer. 2014 Nov 19;14:847. doi: 10.1186/1471-2407-14-847.

5.

Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.

Treszl A, Schally AV, Seitz S, Szalontay L, Rick FG, Szepeshazi K, Halmos G.

Peptides. 2009 Sep;30(9):1643-50. doi: 10.1016/j.peptides.2009.06.007. Epub 2009 Jun 12.

PMID:
19524629
6.

Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers.

Szepeshazi K, Schally AV, Halmos G, Sun B, Hebert F, Csernus B, Nagy A.

Clin Cancer Res. 2001 Sep;7(9):2854-61.

7.

Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.

Föst C, Duwe F, Hellriegel M, Schweyer S, Emons G, Gründker C.

Oncol Rep. 2011 May;25(5):1481-7. doi: 10.3892/or.2011.1188. Epub 2011 Feb 17.

PMID:
21331448
8.

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K.

Cancer Sci. 2012 Sep;103(9):1665-71. doi: 10.1111/j.1349-7006.2012.02359.x. Epub 2012 Aug 1.

9.

Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.

Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F, Halmos G.

Cancer Res. 2000 Jun 1;60(11):2996-3001.

10.

Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.

Kiaris H, Schally AV, Nagy A, Sun B, Szepeshazi K, Halmos G.

Clin Cancer Res. 2000 Feb;6(2):709-17.

11.

CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, Chen KF.

Breast Cancer Res. 2012 Apr 26;14(2):R68.

12.

Somatostatin receptor-targeted anti-cancer therapy.

Sun LC, Coy DH.

Curr Drug Deliv. 2011 Jan;8(1):2-10. Review.

PMID:
21034425
13.

Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research.

Wang K, Xie S, Ren Y, Xia H, Zhang X, He J.

Oncol Rep. 2012 Jun;27(6):1981-9. doi: 10.3892/or.2012.1742. Epub 2012 Mar 22.

PMID:
22446691
14.

IGFBP7 reduces breast tumor growth by induction of senescence and apoptosis pathways.

Benatar T, Yang W, Amemiya Y, Evdokimova V, Kahn H, Holloway C, Seth A.

Breast Cancer Res Treat. 2012 Jun;133(2):563-73. doi: 10.1007/s10549-011-1816-4. Epub 2011 Oct 14.

PMID:
21997538
15.

YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.

Yamanaka K, Nakata M, Kaneko N, Fushiki H, Kita A, Nakahara T, Koutoku H, Sasamata M.

Int J Oncol. 2011 Sep;39(3):569-75. doi: 10.3892/ijo.2011.1077. Epub 2011 Jun 14.

PMID:
21674125
16.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
17.

A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.

Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G.

Eur J Cancer. 2001 Mar;37(5):620-8.

PMID:
11290438
18.

Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238.

Plonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K.

Cancer Res. 1999 Apr 15;59(8):1947-53.

19.

Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238.

Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B, Halmos G.

Cancer. 2001 Sep 1;92(5):1168-76.

PMID:
11571730
20.

Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.

Schubert A, Hawighorst T, Emons G, Gründker C.

Breast Cancer Res Treat. 2011 Dec;130(3):783-90. doi: 10.1007/s10549-011-1358-9. Epub 2011 Jan 30.

PMID:
21279682

Supplemental Content

Support Center